|
|
|
|
|
|
Browse Articles |
|
|
|
|
|
Journal Links |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sci. Lett. J. 2015, 4: 145
|
|
|
|
Research Article
|
|
|
|
|
|
|
Full Text
|
|
|
|
Pegylated solid lipid nanoparticles reconstituted from high-density lipoprotein components for hepatic targeting
|
|
|
|
Ahmad Bani-Jabera,b, Huadong Cuia,d, Ahmed Elsaida, Murat Yalcina, c, Thangirala Sudhaa, Shaker A. Mousaa
|
|
|
|
|
|
|
|
a The Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, 1 Discovery Drive, Room 238, Rensselaer, NY 12144, U.S.A.
b Permanent address: Faculty of Pharmacy, The University of Jordan, Amman, Jordan
c Permanent address: Department of Physiology, Veterinary Medicine Faculty, Uludag University, Gorukle, Bursa, Turkey
d Current address: Pain and Spine Consultants, Brentwood, TN, 37027, U.S.A.
|
|
|
|
|
|
|
|
Abstract |
|
|
|
Pegylated solid lipid nanoparticles encapsulating paclitaxel as a model drug were prepared to target hepatocytes and evaluated in vitro and in vivo. Nanoparticles were prepared by a solvent-emulsification method with composition (w/w) 40% cholesterol esters, 18% glycerol trioleate, 8% cholesterol, and 34% pegylated distearoyl phosphatidylethanolamine. Dynamic light scattering results showed that the void nanoparticles and paclitaxel-loaded nanoparticles had mean sizes of about 154 nm and 158 nm, respectively. Cellular uptake and cytotoxicity in vitro were evaluated by confocal imaging in HepG2 (human hepatocellular carcinoma), MCF7 (human breast adenocarcinoma), and PANC-1 (human pancreatic cancer) cells; HepG2 cells showed the highest nanoparticle uptake. Paclitaxel-loaded nanoparticles or paclitaxel solution were administered by intra-peritoneal injection into mice, and paclitaxel concentrations in plasma, livers, hearts, lungs, and kidneys were analyzed by LC-MS/MS. Paclitaxel-loaded solid lipid nanoparticles achieved longer circulation times in plasma and higher drug accumulation in liver than paclitaxel solution. This formulation has potential application in hepatic carcinoma.
|
|
|
|
|
|
|
|
Keywords
|
|
|
|
Biodistribution; Hepatocytes; High-density lipoprotein; Nanoparticles; Paclitaxel; Solid lipid nanoparticles
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|